Targeted α-therapy (TAT) can eradicate tumor metastases while limiting overall toxicity. One of the most promising α-particle emitters is astatine-211 (211At). However, 211At-carbon bonds are notoriously unstable in vivo and no chelators available. This hampers its adoption TAT. In this study, stability 211At on surface gold nanoparticles (AuNPs) was investigated. The employed AuNPs had sizes 2...

Selected results are presented and discussed concerning nuclear data relevant to the production of innovative medical radionuclides (RNs) of special interest, measurements of excitation functions of the involved nuclear reactions, in comparison with the corresponding theoretical calculations. Moreover, at the Radiochemistry Laboratory of Accelerators and Applied Superconductivity Laboratory, LA...

Background: Most carcinomas are prone to metastasize despite successful treatment of the primary tumor. One way to address this clinical challenge may be targeted therapy with α-emitting radionuclides such as astatine-211 (At). Radioimmunotherapy utilizing α-particle emitting radionuclides is considered especially suitable for the treatment of small cell clusters and single cells, although lesi...

Peritoneal metastasis of gastric cancer (PMGC) is incurable and thus has an extremely poor prognosis. We have found, however, that locoregionally administered trastuzumab armed with astatine-211 (211 At-trastuzumab) is effective against human epidermal growth factor receptor 2 (HER2)-positive PMGC in a xenograft mouse model. We first observed that 211 At-trastuzumab can specifically bind and ef...

BACKGROUND Most carcinomas are prone to metastasize despite successful treatment of the primary tumor. One way to address this clinical challenge may be targeted therapy with α-emitting radionuclides such as astatine-211 (211At). Radioimmunotherapy utilizing α-particle emitting radionuclides is considered especially suitable for the treatment of small cell clusters and single cells, although le...